Fate Therapeutics, Inc. (FATE) NASDAQ
2.60
-0.14(-5.11%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.60
-0.14(-5.11%)
Currency In USD
Address
12278 Scripps Summit Drive
San Diego, CA 92131
United States of America (the)
Phone
858 875 1800
Sector
Healthcare
Industry
Biotechnology
Employees
181
First IPO Date
October 01, 2013
| Name | Title | Pay | Year Born |
| Bahram Valamehr | President, Chief Executive Officer & Director | 964,700 | 1977 |
| Kamal Adawi | CFO & Treasurer | 541,973 | 1979 |
| Cindy R. Tahl | Chief Legal & Compliance Officer and Corporate Secretary | 732,700 | 1973 |
| Martin Hosking | Head of Research | 0 | N/A |
| Kate Duvall | Corporate Controller | 0 | N/A |
| Tunde Babalola | Senior Vice President of Technical Operations & Quality | 0 | N/A |
| Yu Cai | Head of Intellectual Property & Assistant General Counsel | 0 | N/A |
| Andrew Henry | Senior Vice President of Clinical Operations | 0 | 1964 |
| Ryan Douglas | Senior Director of Investor Relations & Business Development | 0 | N/A |
| Jessica Francis | Senior Vice President of Human Resources & Operations | 0 | N/A |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.